Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

Roberto Latagliata; Massimo Breccia; Fausto Castagnetti; Fabio Stagno; Luigiana Luciano; Antonella Gozzini; Stefano Ulisciani; Francesco Cavazzini; Mario Annunziata; Federica Sorà; Antonella Russo Rossi; Patrizia Pregno; Enrico Montefusco; Elisabetta Abruzzese; Elena Crisà; Pellegrino Musto; Mario Tiribelli; Gianni Binotto; Ubaldo Occhini; Costanzo Feo; Paolo Vigneri; Valeria Santini; Carmen Fava; Giannantonio Rosti; Giuliana Alimena

doi:10.1016/j.leukres.2011.05.015

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

Roberto Latagliata, Massimo Breccia, Fausto Castagnetti, Fabio Stagno, Luigiana Luciano, Antonella Gozzini, Stefano Ulisciani, Francesco Cavazzini, Mario Annunziata, Federica Sorà, Antonella Russo Rossi, Patrizia Pregno, Enrico Montefusco, Elisabetta Abruzzese, Elena Crisà, Pellegrino Musto, Mario Tiribelli, Gianni Binotto, Ubaldo Occhini, Costanzo FeoPaolo Vigneri, Valeria Santini, Carmen Fava, Giannantonio Rosti, Giuliana Alimena

IRCCS Centro di Riferimento Oncologico della Basilicata (CROB)

Research output: Contribution to journal › Article › peer-review

Abstract

To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher in patients with 140. mg starting dose (50.0% vs 19.6%, p = 0.001). Grade 3-4 pleuro-pericardial effusions occurred in 10 patients (8.0%). Dose reductions were more common in patients with 140. mg (88.4% vs 26.7%, p<0.001). Of 122 evaluable patients, 72 (59.1%) had cytogenetic response [12 (9.8%) partial, 60 (49.3%) complete]. Overall, 38/60 patients in complete CyR also achieved a molecular response. Cumulative OS at 24 and 48 months were 93.1% (95% CI 88.4-97.8) and 84.2% (95% CI 74.6-93.7). Dasatinib, at the recommended dose of 100. mg/day, is effective and safe also in unselected elderly subjects.

Original language	English
Pages (from-to)	1164-1169
Number of pages	6
Journal	Leukemia Research
Volume	35
Issue number	9
DOIs	https://doi.org/10.1016/j.leukres.2011.05.015
Publication status	Published - Sep 2011

Keywords

Chronic Myeloid Leukaemia
Dasatinib
Elderly
Safety

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Access to Document

10.1016/j.leukres.2011.05.015

Fingerprint Dive into the research topics of 'Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib'. Together they form a unique fingerprint.

Cite this

Latagliata, R., Breccia, M., Castagnetti, F., Stagno, F., Luciano, L., Gozzini, A., Ulisciani, S., Cavazzini, F., Annunziata, M., Sorà, F., Rossi, A. R., Pregno, P., Montefusco, E., Abruzzese, E., Crisà, E., Musto, P., Tiribelli, M., Binotto, G., Occhini, U., ... Alimena, G. (2011). Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Leukemia Research, 35(9), 1164-1169. https://doi.org/10.1016/j.leukres.2011.05.015

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. / Latagliata, Roberto; Breccia, Massimo; Castagnetti, Fausto; Stagno, Fabio; Luciano, Luigiana; Gozzini, Antonella; Ulisciani, Stefano; Cavazzini, Francesco; Annunziata, Mario; Sorà, Federica; Rossi, Antonella Russo; Pregno, Patrizia; Montefusco, Enrico; Abruzzese, Elisabetta; Crisà, Elena; Musto, Pellegrino; Tiribelli, Mario; Binotto, Gianni; Occhini, Ubaldo; Feo, Costanzo; Vigneri, Paolo; Santini, Valeria; Fava, Carmen; Rosti, Giannantonio; Alimena, Giuliana.

In: Leukemia Research, Vol. 35, No. 9, 09.2011, p. 1164-1169.

Research output: Contribution to journal › Article › peer-review

Latagliata, R, Breccia, M, Castagnetti, F, Stagno, F, Luciano, L, Gozzini, A, Ulisciani, S, Cavazzini, F, Annunziata, M, Sorà, F, Rossi, AR, Pregno, P, Montefusco, E, Abruzzese, E, Crisà, E, Musto, P, Tiribelli, M, Binotto, G, Occhini, U, Feo, C, Vigneri, P, Santini, V, Fava, C, Rosti, G & Alimena, G 2011, 'Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib', Leukemia Research, vol. 35, no. 9, pp. 1164-1169. https://doi.org/10.1016/j.leukres.2011.05.015

Latagliata, Roberto ; Breccia, Massimo ; Castagnetti, Fausto ; Stagno, Fabio ; Luciano, Luigiana ; Gozzini, Antonella ; Ulisciani, Stefano ; Cavazzini, Francesco ; Annunziata, Mario ; Sorà, Federica ; Rossi, Antonella Russo ; Pregno, Patrizia ; Montefusco, Enrico ; Abruzzese, Elisabetta ; Crisà, Elena ; Musto, Pellegrino ; Tiribelli, Mario ; Binotto, Gianni ; Occhini, Ubaldo ; Feo, Costanzo ; Vigneri, Paolo ; Santini, Valeria ; Fava, Carmen ; Rosti, Giannantonio ; Alimena, Giuliana. / Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. In: Leukemia Research. 2011 ; Vol. 35, No. 9. pp. 1164-1169.

@article{2be26ff970464ab1956175285c397005,

title = "Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib",

abstract = "To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher in patients with 140. mg starting dose (50.0% vs 19.6%, p = 0.001). Grade 3-4 pleuro-pericardial effusions occurred in 10 patients (8.0%). Dose reductions were more common in patients with 140. mg (88.4% vs 26.7%, p<0.001). Of 122 evaluable patients, 72 (59.1%) had cytogenetic response [12 (9.8%) partial, 60 (49.3%) complete]. Overall, 38/60 patients in complete CyR also achieved a molecular response. Cumulative OS at 24 and 48 months were 93.1% (95% CI 88.4-97.8) and 84.2% (95% CI 74.6-93.7). Dasatinib, at the recommended dose of 100. mg/day, is effective and safe also in unselected elderly subjects.",

keywords = "Chronic Myeloid Leukaemia, Dasatinib, Elderly, Safety",

author = "Roberto Latagliata and Massimo Breccia and Fausto Castagnetti and Fabio Stagno and Luigiana Luciano and Antonella Gozzini and Stefano Ulisciani and Francesco Cavazzini and Mario Annunziata and Federica Sor{\`a} and Rossi, {Antonella Russo} and Patrizia Pregno and Enrico Montefusco and Elisabetta Abruzzese and Elena Cris{\`a} and Pellegrino Musto and Mario Tiribelli and Gianni Binotto and Ubaldo Occhini and Costanzo Feo and Paolo Vigneri and Valeria Santini and Carmen Fava and Giannantonio Rosti and Giuliana Alimena",

year = "2011",

month = sep,

doi = "10.1016/j.leukres.2011.05.015",

language = "English",

volume = "35",

pages = "1164--1169",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "9",

}

TY - JOUR

T1 - Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

AU - Latagliata, Roberto

AU - Breccia, Massimo

AU - Castagnetti, Fausto

AU - Stagno, Fabio

AU - Luciano, Luigiana

AU - Gozzini, Antonella

AU - Ulisciani, Stefano

AU - Cavazzini, Francesco

AU - Annunziata, Mario

AU - Sorà, Federica

AU - Rossi, Antonella Russo

AU - Pregno, Patrizia

AU - Montefusco, Enrico

AU - Abruzzese, Elisabetta

AU - Crisà, Elena

AU - Musto, Pellegrino

AU - Tiribelli, Mario

AU - Binotto, Gianni

AU - Occhini, Ubaldo

AU - Feo, Costanzo

AU - Vigneri, Paolo

AU - Santini, Valeria

AU - Fava, Carmen

AU - Rosti, Giannantonio

AU - Alimena, Giuliana

PY - 2011/9

Y1 - 2011/9

N2 - To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher in patients with 140. mg starting dose (50.0% vs 19.6%, p = 0.001). Grade 3-4 pleuro-pericardial effusions occurred in 10 patients (8.0%). Dose reductions were more common in patients with 140. mg (88.4% vs 26.7%, p<0.001). Of 122 evaluable patients, 72 (59.1%) had cytogenetic response [12 (9.8%) partial, 60 (49.3%) complete]. Overall, 38/60 patients in complete CyR also achieved a molecular response. Cumulative OS at 24 and 48 months were 93.1% (95% CI 88.4-97.8) and 84.2% (95% CI 74.6-93.7). Dasatinib, at the recommended dose of 100. mg/day, is effective and safe also in unselected elderly subjects.

AB - To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher in patients with 140. mg starting dose (50.0% vs 19.6%, p = 0.001). Grade 3-4 pleuro-pericardial effusions occurred in 10 patients (8.0%). Dose reductions were more common in patients with 140. mg (88.4% vs 26.7%, p<0.001). Of 122 evaluable patients, 72 (59.1%) had cytogenetic response [12 (9.8%) partial, 60 (49.3%) complete]. Overall, 38/60 patients in complete CyR also achieved a molecular response. Cumulative OS at 24 and 48 months were 93.1% (95% CI 88.4-97.8) and 84.2% (95% CI 74.6-93.7). Dasatinib, at the recommended dose of 100. mg/day, is effective and safe also in unselected elderly subjects.

KW - Chronic Myeloid Leukaemia

KW - Dasatinib

KW - Elderly

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=80051471275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051471275&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.05.015

DO - 10.1016/j.leukres.2011.05.015

M3 - Article

C2 - 21705080

AN - SCOPUS:80051471275

VL - 35

SP - 1164

EP - 1169

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -